References

1. Sturla, L. M., Fernandez-Teijeiro, A., and Pomeroy, S. L. (2003). Application of microarrays to neurological disease. Arch Neurol 60, 676-682.

2. Whitney, L. W., Ludwin, S. K., McFarland, H. F., and Biddison, W. E. (2001). Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J Neuroimmunol 121, 40-48.

3. Bitsch, A., and Bruck, W. (2002). Differentiation of multiple sclerosis subtypes: implications for treatment. CNS Drugs 16, 405-418.

4. Goodin, D. S., Frohman, E. M., Garmany, G. P. Jr. et al. (2002). Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58, 169-178.

5. Ginsberg, S. D., Hemby, S. E., Lee, V. M., Eberwine, J. H, and Trojanowski, J. Q. (2000). Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Ann Neurol 48, 77-87.

6. Luthi-Carter, R., Strand, A., Peters, N. L. et al. (2000). Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 9, 1259-1271.

7. Mirnics, K., Middleton, F. A., Lewis, D. A., and Levitt, P. (2001). Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends Neurosci 24, 479-486.

8. Alwine, J. C., Kemp, D. J., and Stark, G. R. (1977). Method for detection of specific RNAs in agarose gels by transfer to diazobenzyloxymethyl-paper and hybridization with DNA probes. Proc Natl Acad Sci USA 74, 5350-5354.

9. Liang, P., and Pardee, A. B. (1992). Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257, 967-971.

10. Okubo, K., Hori, N., Matoba, R. et al. (1992). Large scale cDNA sequencing for analysis of quantitative and qualitative aspects of gene expression. Nat Genet 2, 173-179.

11. Adams, M. D., Kelley, J. M., Gocayne, J. D. et al. (1991). Complementary DNA sequencing: expressed sequence tags and human genome project. Science 252, 1651-1656.

12. Velculescu, V. E., Zhang, L., Vogelstein, B., and Kinzler, K. W. (1995). Serial analysis of gene expression. Science 270, 484-487.

13. Schena, M., Shalon, D., Davis, R. W., and Brown, P. O. (1995). Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467-470.

14. Schena, M., Shalon, D., Heller, R., Chai, A., Brown, P. O., and Davis, R. W. (1996). Parallel human genome analysis: micro-array-based expression monitoring of 1000 genes. Proc Natl Acad Sci USA 93, 10614-10619.

15. Jacob, A., Brandt, O., Stephan, A. et al. (2004). Peptide nucleic acid microarrays. Methods Mol Biol 283, 283-293.

16. Maughan, N. J., Lewis, F. A., and Smith, V. (2001). An introduction to arrays. J Pathol 195, 3-6.

17. Duggan, D. J., Bittner, M., Chen, Y., Meltzer, P., and Trent, J. M. (1999). Expression profiling using cDNA microarrays. Nat Genet 21, 10-14.

18. Ramaswamy, S., Tamayo, P., Rifkin, R. et al. (2001). Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci USA 98, 15149-15154.

19. Lewis, F., Maughan, N. J., Smith, V., Hillan, K., and Quirke, P. (2001). Unlocking the archive-gene expression in paraffin-embedded tissue. J Pathol 195, 66-71.

20. Chen, G., Gharib, T. G., Huang, C. C. et al. (2002). Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res 8, 2298-2305.

21. Hanash, S. M. (2001). Global profiling of gene expression in cancer using genomics and proteomics. Curr Opin Mol Ther 3, 538-545.

22. Hanash, S. (2003). Disease proteomics. Nature 422, 226-232.

23. Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C., and Liotta, L. A. (2002). Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 1, 683-695.

24. Evans, G., Wheeler, C. H., Corbett, J. M., and Dunn, M. J. (1997). Construction of HSC-2DPAGE: a two-dimensional gel electro-phoresis database of heart proteins. Electrophoresis 18, 471-479.

25. Li, C., Chen, Z., Xiao, Z. et al. (2003). Comparative proteomics analysis of human lung squamous carcinoma. Biochem Biophys Res Commun 309, 253-260.

26. Joubert-Caron, R., and Caron, M. (2005). Proteome analysis in the study of lymphoma cells. Mass Spectrom Rev 24, 455-468.

27. Alexe, G., Alexe, S., Liotta, L. A., Petricoin, E., Reiss, M., and Hammer, P. L. (2004). Ovarian cancer detection by logical analysis of proteomic data. Proteomics 4, 766-783.

28. Pellois, J. P., Zhou, X., Srivannavit, O., Zhou, T., Gulari, E., and Gao, X. (2002). Individually addressable parallel peptide synthesis on microchips. Nat Biotechnol 20, 922-926.

29. Paweletz, C. P., Charboneau, L., Bichsel, V. E. et al. (2001). Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981-1989.

30. Robinson, W. H., DiGennaro, C., Hueber, W. et al. (2002). Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med 8, 295-301.

31. Sorlie, T., Perou, C. M., Tibshirani, R. et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98, 10869-10874.

32. Perou, C. M., Sorlie, T., Eisen, M. B. et al. (2000). Molecular portraits of human breast tumours. Nature 406, 747-752.

33. Golub, T. R., Slonim, D. K., Tamayo, P. et al. (1999). Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537.

34. Hacia, J. G. (1999). Resequencing and mutational analysis using oligonucleotide microarrays. Nat Genet 21, 42-47.

35. Ramaswamy, S., and Golub, T. R. (2002). DNA microarrays in clinical oncology. J Clin Oncol 20, 1932-1941.

36. Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70.

37. Strausberg, R. L. (2001). The Cancer Genome Anatomy Project: new resources for reading the molecular signatures of cancer. J Pathol 195, 31-40.

38. Alizadeh, A. A., Eisen, M. B., Davis, R. E. et al. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511.

39. DeRisi, J., Penland, L., Brown, P. O. et al. (1996). Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 14, 457-460.

40. Marx, J. (2000). Medicine. DNA arrays reveal cancer in its many forms. Science 289, 1670-1672.

41. Ho, I. A., Lam, P. Y., and Hui, K. M. (2004). Identification and characterization of novel human glioma-specific peptides to potentiate tumor-specific gene delivery. Hum Gene Ther 15, 719-732.

42. Pomeroy, S. L., Tamayo, P., Gaasenbeek, M. et al. (2002). Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415, 436-442.

43. MacDonald, T. J., Brown, K. M., LaFleur, B. et al. (2001). Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 29, 143-152.

44. Hanash, S. (2003). Harnessing immunity for cancer marker discovery. Nat Biotechnol 21, 37-38.

45. Madoz-Gurpide, J., Wang, H., Misek, D. E., Brichory, F., and Hanash, S. M. (2001). Protein based microarrays: a tool for probing the proteome of cancer cells and tissues. Proteomics 1, 1279-1287.

46. Sorlie, T., Tibshirani, R., Parker, J. et al. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100, 8418-8423.

47. Pomeroy, S. L., and Sturla, L. M. (2003). Molecular biology of medulloblastoma therapy. Pediatr Neurosurg 39, 299-304.

48. Wright, G., Tan, B., Rosenwald, A., Hurt, E. H., Wiestner, A., and Staudt, L. M. (2003). A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 100, 9991-9996.

49. Giangaspero, F., Chieco, P., Ceccarelli, C. et al. (1991). 'Desmoplastic' versus 'classic' medulloblastoma: comparison of DNA content, histopathology and differentiation. Virchows Arch A Pathol Anat Histopathol 418, 207-214.

50. Packer, R. J., Sutton, L. N., Elterman, R. et al. (1994). Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81, 690-698.

51. Glauser, T. A., and Packer. R. J. (1991). Cognitive deficits in long-term survivors of childhood brain tumors. Childs Nerv Syst 7, 2-12.

52. Packer, R. J., Goldwein, J., Nicholson, H. S. et al. (1999). Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol 17, 2127-2136.

53. Hidalgo, M., and Rowinsky, E. K. (2000). The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19, 6680-6686.

54. Kim, J. Y., Nelson, A. L., Algon, S. A. et al. (2003). Medul-loblastoma tumorigenesis diverges from cerebellar granule cell differentiation in patched heterozygous mice. Dev Biol 263, 50-66.

55. Kim, J. Y., Sutton, M. E., Lu, D. J. et al. (1999). Activation of neurotrophin-3 receptor TrkC induces apoptosis in medullo-blastomas. Cancer Res 59, 711-719.

56. Segal, R. A., Goumnerova, L. C., Kwon, Y. K., Stiles, C. D., and Pomeroy, S. L. (1994). Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci USA 91, 12867-12871.

57. Herms, J., Neidt, I., Luscher, B. et al. (2000). C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 89, 395-402.

58. Grotzer, M. A., Hogarty, M. D., Janss, A. J. et al. (2001). MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblas-toma. Clin Cancer Res 7, 2425-2433.

59. Scheurlen, W. G., Schwabe, G. C., Joos, S., Mollenhauer, J., Sorensen, N., and Kuhl, J. (1998). Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 16, 2478-2485.

60. Rood, B. R., Zhang, H., Weitman. D. M., and Cogen, P. H. (2002). Hypermethylation of HIC-1 and 17p allelic loss in medulloblastoma. Cancer Res 62, 3794-3797.

61. Waha, A., Koch, A., Meyer-Puttlitz, B. et al. (2003). Epigenetic silencing of the HIC-1 gene in human medulloblastomas. J Neuropathol Exp Neurol 62, 1192-1201.

62. Gajjar, A., Hernan, R., Kocak, M. et al. (2004). Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22, 984-993.

63. Aruga, J., Yokota, N., Hashimoto, M., Furuichi, T., Fukuda, M., and Mikoshiba, K. (1994). A novel zinc finger protein, zic, is involved in neurogenesis, especially in the cell lineage of cerebellar granule cells. J Neurochem 63, 1880-1890.

64. Yokota, N., Aruga, J., Takai, S. et al. (1996). Predominant expression of human zic in cerebellar granule cell lineage and medulloblastoma. Cancer Res 56, 377-383.

65. Fernandez-Teijeiro, A., Betensky, R. A., Sturla, L. M., Kim, J. Y., Tamayo, P., and Pomeroy, S. L. (2004). Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol 22, 994-998.

66. Wechsler-Reya, R. J., and Scott, M. P. (1999). Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog. Neuron 22, 103-114.

67. Hahn, H., Wojnowski, L., Specht, K. et al. (2000). Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem 275, 28341-28344.

68. Gailani, M. R., Bale, S. J., Leffell, D. J. et al. (1992). Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 69, 111-117.

69. Johnson, R. L., Rothman, A. L., Xie, J. et al. (1996). Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272, 1668-1671.

70. Goodrich, L. V., Johnson, R. L., Milenkovic, L., McMahon, J. A., and Scott, M. P. (1996). Conservation of the hedgehog/patched signaling pathway from flies to mice: induction of a mouse patched gene by Hedgehog. Genes Dev 10, 301-312.

71. Romer, J. T., Kimura, H., Magdaleno, S. et al. (2004). Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/—)p53(—/—) mice. Cancer Cell 6, 229-240.

72. Brodeur, G. M. (2003). Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3, 203-216.

73. Rubnitz, J. E., and Pui, C. H. (2003). Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia. Cancer Treat Rev 29, 31-44.

74. Mischel, P. S., and Cloughesy, T. F. (2003). Targeted molecular therapy of GBM. Brain Pathol 13, 52-61.

75. Holland, E. C., Celestino, J., Dai, C., Schaefer, L., Sawaya, R. E., and Fuller, G. N. (2000). Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25, 55-57.

76. Ermoian, R. P., Furniss, C. S., Lamborn, K. R., et al. (2002). Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res 8, 1100-1106.

77. Choe, G., Horvath, S., and Cloughesy, T. F., et al. (2003). Analysis of the phosphatidylinositol 3/-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63, 2742-2746.

78. Druker, B. J. (2002). Perspectives on the development of a molecularly targeted agent. Cancer Cell 1, 31-36.

79. Sawyers, C. L. (2002). Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell 1, 13-15.

80. Betensky, R. A., Louis, D. N., and Cairncross, J. G. (2002). Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 20, 2495-2499.

81. Bianco, R., Shin, I., Ritter, C. A. et al. (2003). Loss of PTEN/ MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22, 2812-2822.

82. Collins, V. P. (2004). Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry 75 Suppl 2, ii2-11.

83. Huang, H., Colella, S., Kurrer, M., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (2000). Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res 60, 6868-6874.

84. Rickman, D. S., Bobek, M. P., Misek, D. E. et al. (2001). Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 61, 6885-6891.

85. Sallinen, S. L., Sallinen, P. K., Haapasalo, H. K. et al. (2000). Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 60, 6617-6622.

86. Shai, R., Shi, T., Kremen, T. J. et al. (2003). Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22, 4918-4923.

87. Hermanson, M., Funa, K., Koopmann, J. et al. (1996). Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res 56, 164-171.

88. Orian, J. M., Vasilopoulos, K., Yoshida, S., Kaye, A. H., Chow, C. W., and Gonzales, M. F. (1992). Overexpression of multiple oncogenes related to histological grade of astrocytic glioma. Br J Cancer 66, 106-112.

89. Khatua, S., Peterson, K. M., Brown, K. M. et al. (2003). Overexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res 63, 1865-1870.

90. Mischel, P. S., Cloughesy, T. F., and Nelson, S. F. (2004). DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci 5, 782-792.

91. Mischel, P. S., Shai, R., Shi, T. et al. (2003). Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22, 2361-2373.

92. Nutt, C. L., Mani, D. R., Betensky, R. A. et al. (2003). Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63, 1602-1607.

93. Oksenberg, D., Marsters, S. A., O'Dowd, B. F. et al. (1992). A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature 360, 161-163.

94. Oda, Y., Owa, T., Sato, T. et al. (2003). Quantitative chemical proteomics for identifying candidate drug targets. Anal Chem 75, 2159-2165.

95. Marton, M. J., DeRisi, J. L., Bennett, H. A. et al. (1998). Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat Med 4, 1293-1301.

96. Clarke, P. A., Hostein, I., Banerji, U. et al. (2000). Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 19, 4125-4133.

97. Ross, D. T., Scherf, U., Eisen, M. B. et al. (2000). Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24, 227-235.

98. Scherf, U., Ross, D. T., Waltham, M. et al. (2000). A gene expression database for the molecular pharmacology of cancer. Nat Genet 24, 236-244.

99. Weinstein, J. N., Myers, T. G., O'Connor, P. M. et al. (1997). An information-intensive approach to the molecular pharmacology of cancer. Science 275, 343-349.

100. Staunton, J. E., Slonim, D. K., Coller, H. A. et al. (2001). Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 98, 10787-10792.

101. Wallqvist, A., Monks, A., Rabow, A. A. et al. (2003). Mining the NCI screening database: explorations of agents involved in cell cycle regulation. Prog Cell Cycle Res 5, 173-179.

102. Sotiriou, C., Powles, T. J., Dowsett, M. et al. (2002). Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 4, R3.

103. Bohen, S. P., Troyanskaya, O. G., Alter, O. et al. (2003). Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci USA 100, 1926-1930.

104. Guerreiro, N., Staedtler, F., Grenet, O., Kehren, J., and Chibout, S. D. (2003). Toxicogenomics in drug development. Toxicol Pathol 31, 471-479.

105. Cheok, M. H., Yang, W., Pui, C. H. et al. (2003). Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 34, 85-90.

106. Smith, A. G., Davies, R., Dalton, T. P. et al. (2003). Intrinsic hepatic phenotype associated with the Cyp1a2 gene as shown by cDNA expression microarray analysis of the knockout mouse. EHP Toxicogenomics 111, 45-51.

107. Sahi, J., Milad, M. A., Zheng, X. et al. (2003). Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor. J Pharmacol Exp Ther 306, 1027-1034.

108. Huang, Y., and Sadee, W. (2003). Drug sensitivity and resistance genes in cancer chemotherapy: a chemogenomics approach. Drug Discov Today 8, 356-363.

109. Clarke, P. A., te Poele, R., Wooster, R., and Workman, P. (2001). Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. Biochem Pharmacol 62(10), 1311-1336.

DNA microarray

_Failures |_Survivors_

lllllllllllllllll—lllllllllllllllllllll

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment